TLR2 and clostridium difficile infection: The present study, we have developed a cost-effective and efficacious recombinant subunit vaccine against CDI, using rlipoA-RBD as a rational design to contain a toll-like receptor 2 agonist (intrinsic adjuvant property) and achieved high yields in E. coli expression system.